Sana Biotechnology Reports on Security Holder Vote

Ticker: SANA · Form: 8-K · Filed: 2025-06-06T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting

TL;DR

Sana Biotech held a shareholder vote on June 5th, details to follow.

AI Summary

Sana Biotechnology, Inc. filed an 8-K on June 6, 2025, reporting on a matter submitted to a vote of its security holders on June 5, 2025. The filing does not provide details on the specific vote or its outcome, but it is a routine disclosure for such events.

Why It Matters

This filing indicates that Sana Biotechnology held a vote of its security holders, a common corporate governance event that can signal important decisions or approvals affecting the company's direction.

Risk Assessment

Risk Level: low — This is a routine corporate filing about a security holder vote, with no immediate financial or operational impact disclosed.

Key Players & Entities

FAQ

What was the specific matter submitted to a vote of Sana Biotechnology's security holders on June 5, 2025?

The filing does not specify the exact matter that was submitted to a vote of security holders on June 5, 2025.

What was the outcome of the vote by Sana Biotechnology's security holders?

The filing does not disclose the outcome or results of the vote by security holders.

Is this 8-K filing related to a specific event or transaction?

This 8-K filing is related to the submission of matters to a vote of security holders.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 5, 2025.

What is the principal executive office address for Sana Biotechnology, Inc.?

The principal executive offices are located at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.

From the Filing

0000950170-25-083044.txt : 20250606 0000950170-25-083044.hdr.sgml : 20250606 20250606160517 ACCESSION NUMBER: 0000950170-25-083044 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250605 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250606 DATE AS OF CHANGE: 20250606 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sana Biotechnology, Inc. CENTRAL INDEX KEY: 0001770121 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39941 FILM NUMBER: 251030530 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (206) 701-7914 MAIL ADDRESS: STREET 1: 188 EAST BLAINE STREET, SUITE 400 CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 sana-20250605.htm 8-K 8-K 0001770121 false 0001770121 2025-06-05 2025-06-05     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025   SANA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter)             Delaware   001-39941   83-1381173 (State or other jurisdiction of incorporation)   (Commission File Number)     (IRS Employer Identification Number) 188 East Blaine Street , Suite 400 Seattle , Washington 98102 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: (206) 701-7914   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   SANA   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐         Item 5.07 Submission of Matters to a Vote of Security Holders.   Sana Biotechnology, Inc. (the “ Company ”) held its 2025 annual meeting of stockholders (the “ Annual Meeting ”) on June 5, 2025. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025.   Proposal 1: The Company’s stockholders elected all the nominees to serve as Class I directors of the Company’s Board of Directors, each to serve for a three-year term expiring at the Company’s 2028 annual meeting of

View on Read The Filing